1.355

2.65% 0.035

Biomea Fusion Inc (BMEA)

Overview News Price History Option Chain Financials Why BMEA Down? Discussions Forecast

Biomea Fusion Inc stock is traded at $1.355, with a volume of 567.05K. It is up +2.65% in the last 24 hours and up +5.86% over the past month. Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

Previous Close:

$1.32

Open:

$1.32

24h Volume:

567.05K

Relative Volume:

0.67

Market Cap:

$98.22M

Revenue:

Net Income/Loss:

$-44.95M

P/E Ratio:

-1.5182

EPS:

-0.8925

Net Cash Flow:

$-56.37M

1W Performance:

+6.69%

1M Performance:

+5.86%

6M Performance:

+1.88%

1Y Performance:

-21.68%

1-Day Range:

$1.30

$1.39

1-Week Range:

$1.26

$1.39

52-Week Range:

$0.8719

$2.99

Biomea Fusion Inc Stock (BMEA) Company Profile

Name

Biomea Fusion Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

(650) 980-9099

Address

1599 INDUSTRIAL ROAD, SAN CARLOS

Employee

Twitter

Next Earnings Date

2026-08-04

Latest SEC Filings

BMEA's Discussions on Twitter

Compare BMEA vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BMEA Biomea Fusion Inc	1.355	95.68M	0	-44.95M	-56.37M	-0.8925
VRTX Vertex Pharmaceuticals Inc	516.25	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	806.82	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	992.77	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	215.15	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.23	39.31B	5.76B	514.49M	1.10B	4.4813

Biomea Fusion Inc Stock (BMEA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-13-26	Initiated	Rodman & Renshaw	Buy
Aug-28-25	Initiated	Jefferies	Buy
Jun-03-25	Resumed	Piper Sandler	Overweight
Oct-09-24	Initiated	Edward Jones	Buy
Sep-27-24	Upgrade	Rodman & Renshaw	Neutral → Buy
Sep-27-24	Upgrade	Truist	Hold → Buy
Aug-29-24	Initiated	CapitalOne	Overweight
Jun-11-24	Downgrade	Truist	Buy → Hold
Jun-07-24	Downgrade	Barclays	Overweight → Equal Weight
Apr-02-24	Downgrade	JP Morgan	Overweight → Neutral
Feb-06-24	Initiated	Truist	Buy
Jul-27-23	Initiated	Scotiabank	Sector Outperform
Jun-26-23	Downgrade	Jefferies	Buy → Hold
May-12-23	Initiated	Barclays	Overweight
Mar-29-23	Reiterated	Oppenheimer	Outperform
Mar-28-23	Reiterated	H.C. Wainwright	Buy
Feb-24-23	Initiated	Citigroup	Buy
Jun-02-22	Resumed	H.C. Wainwright	Buy
Jan-12-22	Initiated	H.C. Wainwright	Buy
Dec-17-21	Initiated	Oppenheimer	Outperform
May-11-21	Initiated	JP Morgan	Overweight
May-11-21	Initiated	Jefferies	Buy
May-11-21	Initiated	Piper Sandler	Overweight

View All

Biomea Fusion Inc Stock (BMEA) Latest News

Aug 14, 2026

Biomea Fusion (NASDAQ:BMEA) Gains Attention As Institutions Expand Exposure - kalkinemedia.com

Aug 14, 2026

Biomea Fusion shares new insights on three stages of type 1 diabetes in expert webinar - Traders Union

Aug 14, 2026

Aug 13, 2026

Biomea Fusion doses first patient in icovamenib-semaglutide study By Investing.com - Investing.com Canada

Aug 13, 2026

Biomea Fusion doses first patient in icovamenib-semaglutide study - Investing.com

Aug 13, 2026

Biomea Fusion Trial Tests Obesity Drug Combo Beyond Weight Loss - Stock Titan

Aug 13, 2026

Aug 12, 2026

Renaissance Technologies LLC Grows Position in Biomea Fusion, Inc. $BMEA - MarketBeat

Aug 12, 2026